Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label Study of the Efficacy and Safety of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Treated With Modified FOLFIRINOX

NCT06353581 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT06353581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06353581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label Study of the Efficacy and Safety of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Treated With Modified FOLFIRINOX
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Unknown status
Start date
February 16, 2022
Completion date
May 8, 2024
Enrollment
78 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic cancer, metastatic pancreatic cancer